Maria Zambon

52.2k total citations · 9 hit papers
277 papers, 19.5k citations indexed

About

Maria Zambon is a scholar working on Epidemiology, Infectious Diseases and Immunology. According to data from OpenAlex, Maria Zambon has authored 277 papers receiving a total of 19.5k indexed citations (citations by other indexed papers that have themselves been cited), including 221 papers in Epidemiology, 105 papers in Infectious Diseases and 37 papers in Immunology. Recurrent topics in Maria Zambon's work include Influenza Virus Research Studies (198 papers), Respiratory viral infections research (168 papers) and SARS-CoV-2 and COVID-19 Research (47 papers). Maria Zambon is often cited by papers focused on Influenza Virus Research Studies (198 papers), Respiratory viral infections research (168 papers) and SARS-CoV-2 and COVID-19 Research (47 papers). Maria Zambon collaborates with scholars based in United Kingdom, United States and Netherlands. Maria Zambon's co-authors include John Wood, Karl G. Nicholson, Joanna Ellis, Iain Stephenson, Nick Andrews, Katja Höschler, Angie Lackenby, Douglas Fleming, Jamie Lopez Bernal and Alan Hay and has published in prestigious journals such as New England Journal of Medicine, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Maria Zambon

270 papers receiving 18.9k citations

Hit Papers

Effectiveness of ... 2003 2026 2010 2018 2021 2013 2010 2003 2020 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
    2021 1.7k citations Jamie Lopez Bernal, Nick Andrews et al. profile →
  2. Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group
    2013 917 citations Maria Zambon et al. profile →
  3. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study
    2010 577 citations Katja Höschler, Pia Hardelid et al. profile →
  4. Influenza
    2003 541 citations Maria Zambon et al. profile →
  5. Duration of infectiousness and correlation with RT-PCR cycle threshold values in cases of COVID-19, England, January to May 2020
    2020 534 citations Jamie Lopez Bernal, Joanna Ellis et al. Eurosurveillance profile →
  6. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction
    2012 436 citations Maria Zambon et al. Eurosurveillance profile →
  7. Unexpected Receptor Functional Mimicry Elucidates Activation of Coronavirus Fusion
    2019 370 citations Maria Zambon et al. profile →
  8. Severe respiratory illness caused by a novel coronavirus, in a patient transferred to the United Kingdom from the Middle East, September 2012
    2012 361 citations A Bermingham, Katja Höschler et al. Eurosurveillance profile →
  9. Influenza
    2022 281 citations Maria Zambon et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Maria Zambon United Kingdom 72 12.1k 8.9k 3.1k 2.5k 2.2k 277 19.5k
Florian Krammer United States 75 11.9k 1.0× 11.0k 1.2× 6.9k 2.2× 4.5k 1.8× 1.1k 0.5× 368 22.9k
Kanta Subbarao United States 81 15.3k 1.3× 14.8k 1.7× 5.9k 1.9× 4.1k 1.7× 1.4k 0.6× 305 27.4k
Arnold S. Monto United States 81 14.6k 1.2× 5.4k 0.6× 1.9k 0.6× 1.5k 0.6× 2.5k 1.1× 328 19.2k
Frederick G. Hayden United States 83 18.6k 1.5× 6.6k 0.7× 3.3k 1.1× 3.1k 1.2× 1.7k 0.8× 237 24.2k
Vincent J. Munster United States 63 10.2k 0.8× 14.9k 1.7× 2.2k 0.7× 2.5k 1.0× 2.2k 1.0× 219 23.0k
Timothy M. Uyeki United States 64 12.1k 1.0× 6.8k 0.8× 1.3k 0.4× 948 0.4× 1.9k 0.9× 235 17.2k
Emmie de Wit United States 48 5.0k 0.4× 8.6k 1.0× 1.6k 0.5× 1.7k 0.7× 1.2k 0.5× 105 13.3k
Theo M. Bestebroer Netherlands 50 9.6k 0.8× 10.3k 1.2× 2.1k 0.7× 2.5k 1.0× 1.5k 0.7× 113 17.6k
Alicia M. Fry United States 69 12.6k 1.0× 4.8k 0.5× 2.0k 0.6× 1.3k 0.5× 1.7k 0.8× 250 16.9k
William Barclay United Kingdom 57 5.8k 0.5× 5.5k 0.6× 3.2k 1.0× 3.0k 1.2× 704 0.3× 213 12.1k

Countries citing papers authored by Maria Zambon

Since Specialization
Citations

This map shows the geographic impact of Maria Zambon's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria Zambon with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria Zambon more than expected).

Fields of papers citing papers by Maria Zambon

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria Zambon. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria Zambon. The network helps show where Maria Zambon may publish in the future.

Co-authorship network of co-authors of Maria Zambon

This figure shows the co-authorship network connecting the top 25 collaborators of Maria Zambon. A scholar is included among the top collaborators of Maria Zambon based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria Zambon. Maria Zambon is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Whitaker, Heather, Freja Kirsebom, Catherine Quinot, et al.. (2025). Effectiveness of Influenza Vaccines and Duration of Protection Against Hospitalisation in England: 2022/2023 and 2023/2024 Seasons. Influenza and Other Respiratory Viruses. 19(12). e70194–e70194.
2.
Zambon, Maria, Puja Myles, & Norio Sugaya. (2025). Use of Influenza Antivirals in Pandemic Response. The Journal of Infectious Diseases. 232(Supplement_3). S177–S190. 6 indexed citations
3.
4.
Williams, David, John S. Tregoning, Arinder Kohli, et al.. (2024). Robust and sensitive amplicon-based whole-genome sequencing assay of respiratory syncytial virus subtype A and B. Microbiology Spectrum. 12(4). e0306723–e0306723. 2 indexed citations
5.
6.
7.
Williams, Thomas, Sandra Jackson, Ian Barr, et al.. (2023). Results from the second WHO external quality assessment for the molecular detection of respiratory syncytial virus, 2019–2020. Influenza and Other Respiratory Viruses. 17(1). e13073–e13073. 4 indexed citations
8.
Boddington, Nicki L., et al.. (2022). Rapid influenza molecular testing in secondary care and influenza surveillance in England: Any impact?. Influenza and Other Respiratory Viruses. 16(5). 937–941. 2 indexed citations
9.
Sinnathamby, Mary, Fiona Warburton, Nick Andrews, et al.. (2021). Uptake and impact of vaccinating primary school children against influenza: Experiences in the fourth season of the live attenuated influenza vaccination programme, England, 2016/2017. Influenza and Other Respiratory Viruses. 16(1). 113–124. 6 indexed citations
10.
Stowe, Julia, Elise Tessier, Hongxin Zhao, et al.. (2021). Interactions between SARS-CoV-2 and influenza, and the impact of coinfection on disease severity: a test-negative design. International Journal of Epidemiology. 50(4). 1124–1133. 154 indexed citations
11.
Lusignan, Simon de, Ruby S. M. Tsang, Oluwafunmi Akinyemi, et al.. (2021). Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort Study. JMIR Public Health and Surveillance. 8(3). e25803–e25803. 4 indexed citations
12.
Hayward, Andrew, Lili Wang, Nilu Goonetilleke, et al.. (2015). Natural T Cell–mediated Protection Against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine. 191(12). 1422–1431. 210 indexed citations
13.
Goonetilleke, Nilu, A Bermingham, Oliver Dukes, et al.. (2015). NATURAL T CELL MEDIATED PROTECTION AGAINST SEASONAL AND PANDEMIC INFLUENZA. UCL Discovery (University College London). 6 indexed citations
14.
Beck, Charles, Rachel Sokal, Richard Puleston, et al.. (2012). Neuraminidase inhibitors for influenza: a review and public health perspective in the aftermath of the 2009 pandemic. Influenza and Other Respiratory Viruses. 7(s1). 14–24. 9 indexed citations
15.
Hardelid, Pia, et al.. (2010). Assessment of baseline age-specific antibody prevalence and incidence of infection to novel influenza AH1N1 2009. Health Technology Assessment. 14(55). 115–92. 89 indexed citations
16.
Radošević, Katarina, Ariane Rodrı́guez, Ratna Mintardjo, et al.. (2008). Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: Impact of distinct additional adjuvants. Vaccine. 26(29-30). 3640–3646. 44 indexed citations
17.
Puzelli, Simona, Livia Di Trani, Concetta Fabiani, et al.. (2006). Reply to Skowronski et al.. The Journal of Infectious Diseases. 193(6). 900–901. 1 indexed citations
18.
Ellis, Joanna, et al.. (2004). Influenza and other respiratory viruses surveillance in the United Kingdom: October 2003 to May 2004. 10 indexed citations
19.
Müller‐Pebody, Berit, W. John Edmunds, Maria Zambon, Nigel Gay, & Natasha S. Crowcroft. (2002). Contribution of RSV to bronchiolitis and pneumonia-associated hospitalizations in English children, April 1995–March 1998. Epidemiology and Infection. 129(1). 99–106. 68 indexed citations
20.
Ellis, Joanna & Maria Zambon. (1997). Molecular analysis of an outbreak of influenza in the United Kingdom. European Journal of Epidemiology. 13(4). 369–372. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Florian Krammer Breakdown of academic impact, for papers by Kanta Subbarao Breakdown of academic impact, for papers by Arnold S. Monto Breakdown of academic impact, for papers by Frederick G. Hayden Breakdown of academic impact, for papers by Vincent J. Munster Breakdown of academic impact, for papers by Timothy M. Uyeki Breakdown of academic impact, for papers by Emmie de Wit Breakdown of academic impact, for papers by Theo M. Bestebroer Breakdown of academic impact, for papers by Alicia M. Fry Breakdown of academic impact, for papers by William Barclay
Rankless by CCL
2026